Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | F10 | P00742 | 11/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6195419 | 0.99 | ATM (0.69) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5734654 | 0.90 | ATM (0.59) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5734070 | 0.89 | SMN1; SMN2 (0.66) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6734223 | 0.89 | ATM (0.64) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5733495 | 0.89 | ATM (0.58) | ATMF10SMN1; SMN2LMNAGAA | |
| SCHEMBL6195975 | 0.88 | F10 (0.57) | ATMF10SMN1; SMN2GAAF2 | |
| Hydrochloric Acid SCHEMBL6198549 | 0.88 | ATM (0.60) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6728205 | 0.88 | ATM (0.55) | ATMF10SMN1; SMN2LMNAGAA | |
| Hydrochloric Acid SCHEMBL6195882 | 0.88 | SMN1; SMN2 (0.64) | ATMF10SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6198681 | 0.88 | F10 (0.55) | ATMF10SMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343530-B1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | claimed |
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | claimed |
| US-20040138231-A1 | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropyl-methylcellulose phthalate polymer | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | claimed |
| US-20040076673-A1 | Oral pharmaceutical composition containing a block copolymer | MATERIAL IMPROVEMENT, LP | 2004-04-22 | — | — | US | claimed |
| EP-1365746-A1 | PHARMACEUTICAL COMPOSITION WHICH COMPRISE A SOLID DISPERSION OF A HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE POLYMER | AstraZeneca AB (SE) | 2003-12-03 | — | — | EP | claimed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | claimed |
| EP-1343530-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | AstraZeneca AB (SE) | 2003-09-17 | — | — | EP | claimed |
| WO-2002067904-A1 | PHARMACEUTICAL COMPOSITION WHICH COMPRISE A SOLID DISPERSION OF A HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE POLYMER | ASTRAZENECA AB (SE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002038184-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | ASTRAZENECA AB (SE) | 2002-05-16 | — | — | WO | claimed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | claimed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | claimed |
| EP-1084118-A1 | REDUCED PARTICLE SIZE FORM OF 1-(6-CHLORONAPHTH-2- YLSULPHONYL) -4- 4-(4PYRIDYL) BENZOYL] PIPERAZINE | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | claimed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | claimed |
| WO-1999057112-A1 | REDUCED PARTICLE SIZE FORM OF 1-(6-CHLORONAPHTH-2- YLSULPHONYL) -4-[4-(4PYRIDYL) BENZOYL] PIPERAZINE | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | claimed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | claimed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | claimed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | claimed |
| JP-11236372-A | — | — | None | — | — | JP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | ATM 3746/4885F10 5/4885SMN1; SMN2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.